Treatment of epidermolysis bullosa simplex with dupilumab

The Journal of DermatologyEarly View LETTER TO THE EDITOR Treatment of epidermolysis bullosa simplex with dupilumab Xiaofang Sun, Xiaofang Sun Department of Dermatology, The Second Affiliated Hospital of Jiaxing University, Zhejiang, ChinaSearch for more papers by this authorJianping Zhang, Jianping Zhang Department of Dermatology, The Second Affiliated Hospital of Jiaxing University, Zhejiang, ChinaSearch for more papers by this authorQiuyan Yang, Qiuyan Yang Department of Dermatology, The Second Affiliated Hospital of Jiaxing University, Zhejiang, ChinaSearch for more papers by this authorJinran Lin, Corresponding Author Jinran Lin [email protected] orcid.org/0000-0002-6816-9369 Department of Dermatology, Huashan Hospital, Fudan University, Shanghai, China Correspondence Jinran Lin, Department of Dermatology, Huashan Hospital, Fudan University, Shanghai, China. Email: [email protected]Search for more papers by this author Xiaofang Sun, Xiaofang Sun Department of Dermatology, The Second Affiliated Hospital of Jiaxing University, Zhejiang, ChinaSearch for more papers by this authorJianping Zhang, Jianping Zhang Department of Dermatology, The Second Affiliated Hospital of Jiaxing University, Zhejiang, ChinaSearch for more papers by this authorQiuyan Yang, Qiuyan Yang Department of Dermatology, The Second Affiliated Hospital of Jiaxing University, Zhejiang, ChinaSearch for more papers by this authorJinran Lin, Corresponding Author Jinran Lin [email protected] orcid.org/0000-0002-6816-9369 Department of Dermatology, Huashan Hospital, Fudan University, Shanghai, China Correspondence Jinran Lin, Department of Dermatology, Huashan Hospital, Fudan University, Shanghai, China. Email: [email protected]Search for more papers by this author First published: 10 November 2023 https://doi.org/10.1111/1346-8138.17037Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinkedInRedditWechat No abstract is available for this article. REFERENCES 1Sprecher E. Epidermolysis bullosa simplex. Dermatol Clin. 2010; 28: 23–32. 2Evtushenko NA, Beilin AK, Kosykh AV, Vorotelyak EA. Keratins as an inflammation trigger point in epidermolysis bullosa simplex. Int J Mol Sci. 2021; 22:12446. 3Papanikolaou M, Onoufriadis A. Prevalence, pathophysiology and management of itch in epidermolysis bullosa. Br J Dermatol. 2021; 184: 816–825. 4Clawson RC, Duran SF, Pariser RJ. Epidermolysis bullosa pruriginosa responding to dupilumab. JAAD Case Rep. 2021; 16: 69–71. 5Su CJ, Tseng HC. Treatment efficacy of dupilumab in a hyper-immunoglobulin E syndrome patient with severe atopic dermatitis. JAAD Case Rep. 2021; 11: 60–62. Early ViewOnline Version of Record before inclusion in an issue ReferencesRelatedInformation